详情页 - 首都医科大学附属北京同仁医院知识库

当前位置：首页 > 详情页

Phase II Study of Orelabrutinib Combined With PD-1 Inhibitor in Relapsed/Refractory Primary Central Nervous System Lymphoma

1| 认领 | 链接全文 |

文献详情

编号/登记号：

注册时间：

研究开始时间：

研究结束时间：

项目类型：

本院角色：

多中心研究：

招募状态：

试验分期：

研究疾病/适应症：

研究类型：

研究负责人：

研究单位： [1]Peking Union Medical College Hospital [2]Beijing Hospital [3]Beijing Tongren Hospital [4]Beijing Luhe Hospital [5]Shanxi Province Renmin Hospital [6]Henan Cancer Hospital [7]Henan Province Renmin Hospital [8]The Second Affiliated Hospital of Dalian Medical University [9]The Forth Hospital of Hebei Medical University [10]The First Hospital of Chinese Medical University [11]Qilu Hospital of Shandong University [12]The First Hospital of Zhengzhou University

关键词： Primary Central Nervous System Lymphoma orelabrutinib PD-1 inhibitor Overall response rate

研究目的：

This is a prospective multicenter single-arm phase II study, and the purpose of this study is to evaluate the efficiency of Orelabrutinib combined with PD-1 inhibitor regimen relapsed/refractory primary intraocular lymphoma. Overall response rate （ORR） after 4 cycles is the primary endpoint.

资源点击量：21169 今日访问量：0 总访问量：1219 更新日期：2025-01-01 建议使用谷歌、火狐浏览器 常见问题